Pioglitazone-Mediated Peroxisome Proliferator-Activated Receptor γ Activation Aggravates Murine Immune-Mediated Hepatitis

The nuclear receptor peroxisome proliferator-activated receptor gamma (PPARγ) regulates target gene expression upon ligand binding. Apart from its effects on metabolism, PPARγ activity can inhibit the production of pro-inflammatory cytokines by several immune cells, including dendritic cells and macrophages. In chronic inflammatory disease models, PPARγ activation delays the onset and ameliorates disease severity. Here, we investigated the effect of PPARγ activation by the agonist Pioglitazone on the function of hepatic immune cells and its effect in a murine model of immune-mediated hepatitis. Cytokine production by both liver sinusoidal endothelial cells (IL-6) and in T cells ex vivo (IFNγ) was decreased in cells from Pioglitazone-treated mice. However, PPARγ activation did not decrease pro-inflammatory tumor necrosis factor alpha TNFα production by Kupffer cells after Toll-like receptor (TLR) stimulation ex vivo. Most interestingly, although PPARγ activation was shown to ameliorate chronic inflammatory diseases, it did not improve hepatic injury in a model of immune-mediated hepatitis. In contrast, Pioglitazone-induced PPARγ activation exacerbated D-galactosamine (GalN)/lipopolysaccharide (LPS) hepatitis associated with an increased production of TNFα by Kupffer cells and increased sensitivity of hepatocytes towards TNFα after in vivo Pioglitazone administration. These results unravel liver-specific effects of Pioglitazone that fail to attenuate liver inflammation but rather exacerbate liver injury in an experimental hepatitis model.

[1]  M. Heming,et al.  Peroxisome Proliferator-Activated Receptor-γ Modulates the Response of Macrophages to Lipopolysaccharide and Glucocorticoids , 2018, Front. Immunol..

[2]  Rui-Jun Zhou,et al.  Apigenin inhibits d-galactosamine/LPS-induced liver injury through upregulation of hepatic Nrf-2 and PPARγ expressions in mice. , 2017, Biochemical and biophysical research communications.

[3]  Shan Li,et al.  PPAR-γ agonist pioglitazone regulates dendritic cells immunogenicity mediated by DC-SIGN via the MAPK and NF-κB pathways. , 2016, International immunopharmacology.

[4]  A. Kei,et al.  The current role of thiazolidinediones in diabetes management , 2016, Archives of Toxicology.

[5]  Ranjit S. Chima,et al.  Pioglitazone reduces inflammation through inhibition of NF-κB in polymicrobial sepsis , 2014, Innate immunity.

[6]  D. Busch,et al.  Liver-primed memory T cells generated under noninflammatory conditions provide anti-infectious immunity. , 2013, Cell reports.

[7]  M. Odenthal,et al.  TNF-induced target cell killing by CTL activated through cross-presentation. , 2012, Cell reports.

[8]  J. Bassaganya-Riera,et al.  The Role of T cell PPAR γ in mice with experimental inflammatory bowel disease , 2010, BMC gastroenterology.

[9]  S. Biswas,et al.  Endotoxin tolerance: new mechanisms, molecules and clinical significance. , 2009, Trends in immunology.

[10]  Michael Famulok,et al.  The nuclear receptor PPARγ selectively inhibits Th17 differentiation in a T cell–intrinsic fashion and suppresses CNS autoimmunity , 2009, The Journal of experimental medicine.

[11]  T. Klockgether,et al.  Increased Antigen Cross-Presentation but Impaired Cross-Priming after Activation of Peroxisome Proliferator-Activated Receptor γ Is Mediated by Up-Regulation of B7H11 , 2009, The Journal of Immunology.

[12]  S. Hartmann,et al.  Systemic PPARgamma ligation inhibits allergic immune response in the skin. , 2008, The Journal of investigative dermatology.

[13]  B. Staels,et al.  Regulation of Macrophage Functions by PPAR-&agr;, PPAR-&ggr;, and LXRs in Mice and Men , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[14]  Lieping Chen,et al.  Tolerogenic maturation of liver sinusoidal endothelial cells promotes B7‐homolog 1‐dependent CD8+ T cell tolerance , 2007, Hepatology.

[15]  Laszlo Nagy,et al.  PPARγ in immunity and inflammation: cell types and diseases , 2007 .

[16]  T. Klockgether,et al.  Peroxisome Proliferator-Activated Receptor γ Control of Dendritic Cell Function Contributes to Development of CD4+ T Cell Anergy , 2007, The Journal of Immunology.

[17]  T. Papadopoulos,et al.  IL‐10, regulatory T cells, and Kupffer cells mediate tolerance in concanavalin A–induced liver injury in mice , 2007, Hepatology.

[18]  V. Cryns,et al.  Peroxisome Proliferator-activated Receptor γ Agonists Promote TRAIL-induced Apoptosis by Reducing Survivin Levels via Cyclin D3 Repression and Cell Cycle Arrest* , 2005, Journal of Biological Chemistry.

[19]  K. Tolman,et al.  Hepatotoxicity of the thiazolidinediones. , 2003, Clinics in liver disease.

[20]  O. Cummings,et al.  Severe but reversible cholestatic liver injury after pioglitazone therapy. , 2002, Annals of internal medicine.

[21]  C. Brosnan,et al.  Peroxisome proliferator‐activated receptor‐γ agonists prevent experimental autoimmune encephalomyelitis , 2002 .

[22]  J. Lefkowitch,et al.  Mixed HepatocellularCholestatic Liver Injury after Pioglitazone Therapy , 2002, Annals of Internal Medicine.

[23]  H. Nawata,et al.  Activation of retinoic X receptor and peroxisome proliferator–activated receptor‐γ inhibits nitric oxide and tumor necrosis factor‐α production in rat Kupffer cells , 2001 .

[24]  T. Papadopoulos,et al.  Importance of Kupffer cells for T-cell-dependent liver injury in mice. , 2000, The American journal of pathology.

[25]  B. Neuschwander‐Tetri,et al.  Troglitazone-Induced Hepatic Failure Leading to Liver Transplantation: A Case Report , 1998, Annals of Internal Medicine.

[26]  P. Watkins,et al.  Hepatic dysfunction associated with troglitazone. , 1998, The New England journal of medicine.

[27]  Christopher K. Glass,et al.  The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation , 1998, Nature.

[28]  B. Seed,et al.  PPAR-γ agonists inhibit production of monocyte inflammatory cytokines , 1998, Nature.

[29]  G. Gerken,et al.  Regulation of endotoxin‐induced IL‐6 production in liver sinusoidal endothelial cells and Kupffer cells by IL‐10 , 1997, Clinical and experimental immunology.

[30]  G. Gerken,et al.  Role of sinusoidal endothelial cells of the liver in concanavalin A‐induced hepatic injury in mice , 1996, Hepatology.

[31]  A. Morelli,et al.  Interleukin 10 reduces lethality and hepatic injury induced by lipopolysaccharide in galactosamine-sensitized mice. , 1996, Gastroenterology.

[32]  N. Van Rooijen,et al.  Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. , 1994, Journal of immunological methods.

[33]  A. Wendel,et al.  A T cell-dependent experimental liver injury in mice inducible by concanavalin A. , 1992, The Journal of clinical investigation.

[34]  C. Galanos,et al.  Tumor necrosis factor alpha mediates lethal activity of killed gram-negative and gram-positive bacteria in D-galactosamine-treated mice , 1991, Infection and immunity.

[35]  C. Galanos,et al.  Induction of tolerance to lipopolysaccharide (LPS)-D-galactosamine lethality by pretreatment with LPS is mediated by macrophages , 1988, Infection and immunity.

[36]  W. Reutter,et al.  Galactosamine-induced sensitization to the lethal effects of endotoxin. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[37]  T. Ikeda.  Drug-induced idiosyncratic hepatotoxicity: prevention strategy developed after the troglitazone case. , 2011, Drug metabolism and pharmacokinetics.

[38]  Gunther Hartmann,et al.  Virally infected mouse liver endothelial cells trigger CD8+ T-cell immunity. , 2010, Gastroenterology.

[39]  B. Staels,et al.  Regulation of Macrophage Functions by PPAR-&agr;, PPAR-&ggr;, and LXRs in Mice and Men , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[40]  L. Nagy,et al.  PPARgamma in immunity and inflammation: cell types and diseases. , 2007, Biochimica et biophysica acta.

[41]  F. Chen,et al.  Peroxisome proliferator-activated receptor gamma agonists promote TRAIL-induced apoptosis by reducing survivin levels via cyclin D3 repression and cell cycle arrest. , 2005, The Journal of biological chemistry.

[42]  C. Brosnan,et al.  Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis. , 2002, Annals of neurology.

[43]  H. Nawata,et al.  Activation of retinoic X receptor and peroxisome proliferator-activated receptor-gamma inhibits nitric oxide and tumor necrosis factor-alpha production in rat Kupffer cells. , 2001, Hepatology.